Previous 10 | Next 10 |
June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. These small-cap biotechnology stocks when held in the long term can...
Gainers: WW +11.8% . NYMT +8.3% . BGG +7.9% . INFN +7.1% . MBIO +4.1% . More news on: WW International, Inc., New York Mortgage Trust, Inc., Briggs & Stratton Corporation, Stocks on the move, , Read more ...
The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with this Read more ...
Constellation Pharmaceuticals (NASDAQ: CNST ) announces new data from an open-label Phase 2 clinical trial, MANIFEST , evaluating CPI-0610 in patients with a rare type of bone marrow cancer called myelofibrosis. The results were virtually presented at EHA. More news on: Constellation Ph...
Constellation Pharmaceuticals (NASDAQ: CNST ) provides updates on the MANIFEST trial of CPI-0610 in myelofibrosis (MF). The data reflect an analysis of clinical activity in 51 first-line and 73 second-line patients. More news on: Constellation Pharmaceuticals, Inc., Healthcare stock...
Spleen response rates in first-line patients at 12 weeks and 24 weeks in line with previously reported data and differentiated from standard of care Spleen responses demonstrated in non-transfusion-dependent second-line patients as a monotherapy and add-on to ruxolitinib Conversion...
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an ...
Constellation Pharmaceuticals (NASDAQ: CNST ) appoints Jeffrey Humphrey, M.D., as Chief Medical Officer (CMO), effective June 22. More news on: Constellation Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jeffrey Humphrey, M.D., will join Constellation Pharma...
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an u...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...